Ken Griffin Age X Therapeutics, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.33 - $0.74 $7,077 - $15,871	21,448 New	21,448 $8,000
Q2 2023 Aug 14, 2023	SELL	$0.45 - $0.89 $1,223 - $2,419	-2,719 Reduced 20.26%	10,702 $9,000
Q1 2023 May 15, 2023	BUY	$0.56 - $0.8 $7,515 - $10,736	13,421 New	13,421 $8,000
Q3 2022 Nov 14, 2022	SELL	$0.55 - $0.74 $3,293 - $4,431	-5,988 Reduced 37.39%	10,029 $6,000
Q2 2022 Aug 15, 2022	SELL	$0.57 - $1.0 $13,976 - $24,520	-24,520 Reduced 60.49%	16,017 $9,000
Q3 2021 Nov 15, 2021	BUY	$0.93 - $1.54 $37,699 - $62,426	40,537 New	40,537 $38,000
Q4 2020 Feb 16, 2021	SELL	$0.8 - $2.56 $19,591 - $62,691	-24,489 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$0.79 - $1.52 $10,471 - $20,147	13,255 Added 117.99%	24,489 $20,000
Q2 2020 Aug 14, 2020	SELL	$0.68 - $1.13 $2,788 - $4,634	-4,101 Reduced 26.74%	11,234 $11,000
Q1 2020 May 15, 2020	BUY	$0.78 - $1.95 $11,961 - $29,903	15,335 New	15,335 $14,000

Ticker AGE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,945,100
Description
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-rel...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.